The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Tmoyan N.A.

National Medical Research Center of Cardiology, Moscow, Russia

Ezov M.V.

Federation State budget organization National Medical Research Center of Cardiology of the Ministry of the Russian Federation, Moscow, Russia

Afanasieva O.I.

Federation State budget organization National Medical Research Center of Cardiology of the Ministry of the Russian Federation, Moscow, Russia

Klesareva E.A.

Federation State budget organization National Medical Research Center of Cardiology of the Ministry of the Russian Federation, Moscow, Russia

Afanasieva M.I.

Federation State budget organization National Medical Research Center of Cardiology of the Ministry of the Russian Federation, Moscow, Russia

Balakhonova T.V.

Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks Minzdravsotsrazvitiia RF, Moskva

Pokrovsky S.N.

Federation State budget organization National Medical Research Center of Cardiology of the Ministry of the Russian Federation, Moscow, Russia

Association of lipoprotein (a) with ischemic stroke and stenotic carotid atherosclerosis

Authors:

Tmoyan N.A., Ezov M.V., Afanasieva O.I., Klesareva E.A., Afanasieva M.I., Balakhonova T.V., Pokrovsky S.N.

More about the authors

Read: 2910 times


To cite this article:

Tmoyan NA, Ezov MV, Afanasieva OI, Klesareva EA, Afanasieva MI, Balakhonova TV, Pokrovsky SN. Association of lipoprotein (a) with ischemic stroke and stenotic carotid atherosclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(3‑2):42‑48. (In Russ.)
https://doi.org/10.17116/jnevro202012003242

Recommended articles:
Anesthetic mana­gement of endo­vascular procedures in patients with ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):20-25
Socio-economic damage caused by elevated low-density lipo­protein cholesterol levels. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):88-98
A clinical case of treating a patient with severe ischemic stroke and cancer. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):114-117

References:

  1. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711. https://doi.org/10.1016/j.jacc.2016.11.042
  2. Feigin VL, Norrving B, Mensah GA. Global Burden of Stroke. Circ Res. 2017;120(3):439-448. https://doi.org/10.1161/CIRCRESAHA.116.308413
  3. Amarenco P, Lavallée PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, Anticoli S, Audebert H, Bornstein NM, Caplan LR, Correia M, Donnan GA, Ferro JM, Gongora-Rivera F, Heide W, Hennerici MG, Kelly PJ, Král M, Lin HF, Molina C, Park JM, Purroy F, Rothwell PM, Segura T, Školoudík D, Steg PG, Touboul PJ, Uchiyama S, Vicaut É, Wang Y, Wong LKS; TIAregistry.org Investigators. Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. N Engl J Med. 2018;378(23):2182-2190. https://doi.org/10.1056/NEJMoa1802712
  4. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
  5. Afanasieva OI, Ezhov MV, Razova OA, Afanasieva MI, Utkina EA, Pokrovsky SN. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Atherosclerosis. 2018;277:477-482. https://doi.org/10.1016/j.atherosclerosis.2018.08.011
  6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
  7. Dahlen GH. Incidence of Lp(a) among populations. In: Scanu A.M., editor. Lipoprotein(a). New York: Academic Press; 1990.
  8. Költringer P, Jürgens G. A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis. 1985;58(1-3):187-198.
  9. Zenker G, Költringer P, Boné G, Niederkorn K, Pfeiffer K, Jürgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17(5):942-945.
  10. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA. 1995;273(16):1269-1273.
  11. Danik SJ, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006;296(11):1363-1370. https://doi.org/10.1001/jama.296.11.1363
  12. Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32(12):3058-3065. https://doi.org/10.1161/atvbaha.112.255521
  13. Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U, Steinhagen-Thiessen E, Endres M, Ebinger M. Lipoprotein(a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242(2):496-503. https://doi.org/10.1016/j.atherosclerosis.2015.08.021
  14. Borrelli MJ, Youssef A, Boffa MB, Koschinsky ML. New Frontiers in Lp(a)-Targeted Therapies. Trends Pharmacol Sci. 2019;40(3):212-225. https://doi.org/10.1016/j.tips.2019.01.004
  15. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. https://doi.org/10.1093/eurheartj/ehw272
  16. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):596-646. https://doi.org/10.1161/CIR.0000000000000678
  17. Ezhov MV, Sergienko IV, Aronov DM, Arabidze GG, Akhmedzhanov NM, Bazhan SS, Balakhonova TV, Barbarash OL, Boytsov SA, Bubnova MG, Voevoda MI, Galyavich AS, Gornyakova NB, Gurevich VS, Drapkina OM, Duplyakov DV, Yeregin SYa, Zubareva MYu, Karpov RS, Karpov YuA, Koziolova NA, Konovalov GA, Konstantinov VO, Kosmacheva ED, Martynov AI, Nebieridze DV, Pokrovsky SN, Ragino YuI, Skibitsky VV, Smolenskaya OG, Chazova IE, Shalnova SA, Shaposhnik II, Kukharchuk VV. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Revision VI. The Journal of Atherosclerosis and Dyslipidemias. 2017;3:5-22. (In Russ.)
  18. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953-1975. https://doi.org/10.1194/jlr.R071233
  19. Albers JJ, Slee A, O’Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1575-1579. https://doi.org/10.1016/j.jacc.2013.06.051
  20. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635-642. https://doi.org/10.1161/circulationaha.113.004406
  21. Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White HD, Colquhoun DM, Blankenberg S, Sullivan DR. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33(12):2902-2908. https://doi.org/10.1161/atvbaha.113.302479

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.